Jaguar Health Inc. announced that the Australian Patent Office has issued a new patent to its family company, Napo Pharmaceuticals, for methods of treating short bowel syndrome $(SBS)$, bile acid diarrhea, and diarrhea associated with small intestine resection or gallbladder removal in patients using an inhibitor of chloride-ion transport such as crofelemer. The company stated that this new patent expands international intellectual property protection for crofelemer's development in short bowel syndrome with intestinal failure and supports its strategy to advance crofelemer in rare pediatric intestinal failure disorders.